Rhea N Coler - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Rhea N Coler

Showing results (71-80 of 132) with videos related to

Pageof 14

Sort By:

Immunohorizons|April 26, 2025

Characterizing TLR4 agonist EmT4™ as an anti-Mycobacterium tuberculosis vaccine adjuvantSasha E Larsen, Maham Rais, Valerie A Reese, et al.

Frontiers in Immunology|March 9, 2018

Improved Immune Responses in Young and Aged Mice with Adjuvanted Vaccines against H1N1 Influenza InfectionSusan L Baldwin, Fan-Chi Hsu, Neal Van Hoeven, et al.

Journal of Controlled Release : Official Journal of the Controlled Release Society|August 13, 2013

Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosisMark T Orr, Christopher B Fox, Susan L Baldwin, et al.

Vaccine|August 10, 2017

Broadened immunity and protective responses with emulsion-adjuvanted H5 COBRA-VLP vaccinesJames D Allen, Simon O Owino, Donald M Carter, et al.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 10, 2025

From Yesterday to Tomorrow: How Vaccine Platforms Have Shaped the Vaccine and Treatment Evaluation UnitsDavid M Dobrzynski, Daniel S Graciaa, Tara M Babu, et al.

Colloids and Surfaces. B, Biointerfaces|September 15, 2009

Physicochemical characterization and biological activity of synthetic TLR4 agonist formulationsRyan C Anderson, Christopher B Fox, Timothy S Dutill, et al.

Scientific Reports|April 28, 2021

Subunit vaccine protects against a clinical isolate of Mycobacterium avium in wild type and immunocompromised mouse modelsSasha E Larsen, Valerie A Reese, Tiffany Pecor, et al.

Frontiers in Immunology|December 24, 2024

Understanding the development of tuberculous granulomas: insights into host protection and pathogenesis, a review in humans and animalsJiwon Lyu, Drew E Narum, Susan L Baldwin, et al.

European Journal of Immunology|May 30, 2013

MyD88 and TRIF synergistic interaction is required for TH1-cell polarization with a synthetic TLR4 agonist adjuvantMark T Orr, Malcolm S Duthie, Hillarie Plessner Windish, et al.

Antimicrobial Agents and Chemotherapy|September 19, 2019

Prophylaxis of <i>Mycobacterium tuberculosis</i> H37Rv Infection in a Preclinical Mouse Model via Inhalation of Nebulized Bacteriophage D29Nicholas B Carrigy, Sasha E Larsen, Valerie Reese, et al.

Pageof 14

Search research articles

Showing results (71-80 of 132) with videos related to

Sort By:

Pageof 14

Immunohorizons|April 26, 2025

Characterizing TLR4 agonist EmT4™ as an anti-Mycobacterium tuberculosis vaccine adjuvantSasha E Larsen, Maham Rais, Valerie A Reese, et al.

Frontiers in Immunology|March 9, 2018

Improved Immune Responses in Young and Aged Mice with Adjuvanted Vaccines against H1N1 Influenza InfectionSusan L Baldwin, Fan-Chi Hsu, Neal Van Hoeven, et al.

Journal of Controlled Release : Official Journal of the Controlled Release Society|August 13, 2013

Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosisMark T Orr, Christopher B Fox, Susan L Baldwin, et al.

Vaccine|August 10, 2017

Broadened immunity and protective responses with emulsion-adjuvanted H5 COBRA-VLP vaccinesJames D Allen, Simon O Owino, Donald M Carter, et al.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 10, 2025

From Yesterday to Tomorrow: How Vaccine Platforms Have Shaped the Vaccine and Treatment Evaluation UnitsDavid M Dobrzynski, Daniel S Graciaa, Tara M Babu, et al.

Colloids and Surfaces. B, Biointerfaces|September 15, 2009

Physicochemical characterization and biological activity of synthetic TLR4 agonist formulationsRyan C Anderson, Christopher B Fox, Timothy S Dutill, et al.

Scientific Reports|April 28, 2021

Subunit vaccine protects against a clinical isolate of Mycobacterium avium in wild type and immunocompromised mouse modelsSasha E Larsen, Valerie A Reese, Tiffany Pecor, et al.

Frontiers in Immunology|December 24, 2024

Understanding the development of tuberculous granulomas: insights into host protection and pathogenesis, a review in humans and animalsJiwon Lyu, Drew E Narum, Susan L Baldwin, et al.

European Journal of Immunology|May 30, 2013

MyD88 and TRIF synergistic interaction is required for TH1-cell polarization with a synthetic TLR4 agonist adjuvantMark T Orr, Malcolm S Duthie, Hillarie Plessner Windish, et al.

Antimicrobial Agents and Chemotherapy|September 19, 2019

Prophylaxis of <i>Mycobacterium tuberculosis</i> H37Rv Infection in a Preclinical Mouse Model via Inhalation of Nebulized Bacteriophage D29Nicholas B Carrigy, Sasha E Larsen, Valerie Reese, et al.

Pageof 14